Drugs / BAFISONTAMAB
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07649655 | Jul 2026 → Mar 2028 expected | colorectal cancer | Shanghai EpimAb Biotherapeutics Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT05498389 | Jun 2023 → Jul 2024 | non-small cell lung carcinoma | Shanghai EpimAb Biotherapeutics Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/2 | NCT05176665 | Oct 2021 → Dec 2025 overdue | carcinoid tumor, metastatic neoplasm | Shanghai EpimAb Biotherapeutics Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03797391 | Dec 2018 → Mar 2025 | metastatic neoplasm, non-small cell lung carcinoma | Shanghai EpimAb Biotherapeutics Co., Ltd. | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07314294 | Dec 2025 → Dec 2027 expected | colorectal cancer | Shanghai EpimAb Biotherapeutics Co., Ltd. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2022-06-08 | Shanghai EpimAb Biotherapeutics Co., Ltd. | Regulatory EpimAb Biotherapeutics Announces U.S. FDA Clearance of IND Application for Phase Ib/II Trial of EMB-01 in Combination with Tagrisso® for Non-Small Cell Lung Cancer epimab.com ↗ |
| 2020-06-22 | Shanghai EpimAb Biotherapeutics Co., Ltd. | Results EpimAb Biotherapeutics Presents Preclinical Data Characterizing EMB-01 at AACR Virtual Annual Meeting II epimab.com ↗ |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-06-08 | Shanghai EpimAb Biotherapeutics Co., Ltd. | EpimAb Biotherapeutics Announces U.S. FDA Clearance of IND Application for Phase Ib/II Trial of EMB-01 in Combination with Tagrisso® for Non-Small Cell Lung Cancer epimab.com ↗ |
| 2020-06-22 | Shanghai EpimAb Biotherapeutics Co., Ltd. | EpimAb Biotherapeutics Presents Preclinical Data Characterizing EMB-01 at AACR Virtual Annual Meeting II epimab.com ↗ |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BAFISONTAMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594472 ↗ |
| Known as | EMB-01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07314294 ↗ |
| Known as | FIT-013a | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594472 ↗ |
| Action | Inhibit | “EMB-01 and osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth in this type of cancer.” NCT05498389 ↗ |
| Modality | Monoclonal antibody | — CHEMBL4594472 ↗ |
| Route | Intravenous | “receive intravenous infusions of EMB01” NCT03797391 ↗ |
| Target | EGFR | “Epidermal growth factor receptor (EGFR)” NCT03797391 ↗ |
| Target | MET | “c-Mesenchymal-Epithelial Transition (cMet)” NCT03797391 ↗ |